ESMO Asia 2022 | HIMALAYA trial: Asian subgroup results

Stephen L. Chan, MBBS (HK), MRCP (UK), FHKCP, FHKAM (Medicine), FRCP (Edin), FRCP (Lond), Chinese University of Hong Kong, Hong Kong, talks on the Phase III HIMALAYA trial (NCT03298451), investigating durvalumab and tremelimumab in the first-line setting for patients with hepatocellular carcinoma (HCC). Patients received either durvalumab monotherapy, durvalumab plus tremelimumab, or sorafenib monotherapy. Dr Chan discusses results from the Asian subgroup population of the trial. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.